

412th OMICS International Conference

World Bio Summit & Expo

November 02-04, 2015 Dubai, UAE



Giuseppe Mucci

Bioscience Clinic Middle East, UAE

Autologous adipose derived stem cell, the gold standard in cartilage regeneration and soft

Scientific innovations from the last year have led to a strong acceleration of the entrance of ADSC in the world of therapies. In recent months, several studies have demonstrated the effectiveness of these cells in cancer therapies. There have been studies which have demonstrated the significant biological safety of ADSC. Importantly, these therapies have permitted the elimination of the need for products derived from animal mediums (bovine fetal serum) during the expansion process, assuring a higher level of compliance with GMP quality standards.

The new culture medium that has been introduced, is the platelet lysate which has sped up the proliferation process in half the time of cultivation, at the same time making the final product safer. In addition to the reduction of the time expansion, cell proliferation has increased ten times more than precedent culture techniques. Therefore in addition to making the product more safe and effective, there has been a drastic reduction in production costs, which has resulted in more cost effective use of autologous expanded ADSC's for patients. An important clinical study conducted by the University of Copenhagen, published by the Lancet in late 2013, has demonstrated the effectiveness of ADSC in soft tissue augmentation making it a viable alternative to the use of implants or fillers for body shaping or face contour.

A clinical study funded by the European Union with funding of the 7th Framework Programme, which involved the most important European universities in the field of orthopedics, and lasted 54 months, analyzed the application of ADSC in the treatment of cartilage degeneration (osteoarthritis). This clinical trial (ADIPOA), in addition to demonstrating the safety and efficacy of ADSC in the treatment of osteoarthritis, also identified the ideal dosage for this disease that until now had not yet known.

Biography

Born May 29, 1961 Italy, Giuseppe Mucci started off his journey studying at the University of Urbino "Carlo Bo" in the Faculty of Medicine and earned a degree in Physical Education later he specialized in psycho-motility. He has been always interested in all innovative approaches in the medical field so that in his business he could positively improve the health of humanity in respect of human physiology, avoiding chemistry and invasive surgery. He has covered important roles in introducing the most advanced medical informatics in medical nutrition therapy and body composition, as well as having transferred the innovation of the aerospace technology for the early detection of melanoma by video-dermoscopy to optical probe. After a solid introduction into the world of medicine, Giuseppe then lifted his career by founding his company in 1999, operating in the sector of equipment and biotechnology. Giuseppe Mucci has always considered knowledge as a cornerstone in the development of his company and of the surrounding world, for this reason in 2005 he launched the Bioscience Foundation (UK) dedicated to knowledge sharing, content management, T-learning and peer-to-peer learning in medical science. In the following year he established Bioscience Institute in San Marino Italy, built as a Cell Factory taking advantage of the latest technological solutions available on the market at the time.

g.mucci@htgroupsa.com